Pharmaceutical filing citing a New England Journal of Medicine paper — Traws Pharma, 2025-05-27
Traws PharmaTraws PharmaNASDAQ TRAW
Filings SEC · Quote Yahoo cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which the paper was written and the scope it actually demonstrated in sequence. The stock price movement for one month following the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure is written in the press release as follows:
When a U.S.-listed company has something to inform its shareholders, it submits a Form 8-K to the Securities and Exchange Commission. The item numbers of the document filed by Traws Pharma on 2025-05-27 were 7.01 Reg FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits. The company cited a paper published in New England Journal of Medicine in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
TRAW information. 2. https://www.nejm.org/doi/full/10.1056/NEJMsb2506929 3. BIKTARVY is a registered trademark o f G ilead Science, Inc. 4.
The reader should first check where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has read only the abstract, cannot provide an answer to that.
The scope of the paper mentioned in the abstract is limited to this.
The paper's title is An Evidence-Based Approach to Covid-19 Vaccination and it was published in New England Journal of Medicine on 2025-05-20. The authors are affiliated with the Center for Biologics Evaluation and Research · United States Food and Drug AdministrationFood and Drug Administration
Regulator · Website. The summary at the beginning of the paper is called abstract. This article has read only up to this point. The paragraph was written by a person after filtering a draft generated by a machine reading the abstract, and thus it is of a different grade than a full-text review.
This article is a commentary published in the medical journal NEJM, not a research paper. Since the abstract is not publicly available, it has not been summarized. What can be known from the title is that it is a discussion on how to determine the administration of the coronavirus vaccine based on evidence. It is not an article containing new experimental results.
What the abstract does not answer remains in the full text and the appendix. This article, which has not gone beyond that, leaves the blanks as they are. Readers should compare the two citations above to determine which sentence in the abstract corresponds to the cited passage by the company.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In calendar terms, 20 trading days are about a month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | +12.1% | The extent of movement before the filing |
| On the day of the filing | +5.1% | On the filing day or the first trading day after |
| Accumulated over +1 to +5 trading days | +36.9% | One week |
| +1 to +20 trading days cumulative | +5.5% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +5.5% in this case is within the bottom 74% of the 142 samples and is within the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +5.5% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to the next case.
There are two more cases where the same company wrote papers in 8-K, and they are placed together in the table below.
| Disclosure date | the journal of the paper | excess return for one month |
|---|---|---|
| 2025-06-03 | British Journal of Dermatology | −27.4% |
| 2025-06-30 | New England Journal of Medicine | +0.1% |
after the filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content, as the numbers specify whether it was an earnings announcement or a contract. The details of what occurred are read in the original text of each link.
- 2025-06-03 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements and exhibits
- 2025-06-30 8-K Item 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements · Exhibits
- 2025-07-03 8-K Item 5.02 — Officer and director changes
What this article does not answer
This article, which reads only abstracts, does not answer how the paper reviewed what method, what it re-examined, and how far it showed. How often the paper cited by the company was cited afterward can be rechecked by OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Term explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company alone after removing the portion where the market as a whole rises or falls.
- Trading day
- A date counted only on days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.